A PHASE 1B RANDOMIZED, DOUBLE BLINDED, PLACEBO CONTROLLED, ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE DOSES OF ARCT-810 IN CLINICALLY STABLE PATIENTS WITH ORNITHINE TRANSCARBAMYLASE DEFICIENCY

Registry ID

ARCT-810-02

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ARCTURUS THERAPEUTICS, INC.

Last update

2021-01-15

Conditions

• ORNITHINE TRANSCARBAMYLASE DEFICIENCY

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ADENOASSOCIATED VIRUS SEROTYPE 8 (AAV8)-MEDIATED GENE TRANSFER OF HUMAN ORNITHINE TRANSCARBAMYLASE (OTC) IN PATIENTS WITH LATE-ONSET OTC DEFICIENCY

View on source registry